@article {Dalton2021.02.02.21250541, author = {Kathryn R. Dalton and Kathy Ruble and Laurel E. Redding and Daniel O. Morris and Noel T. Mueller and Roland J. Thorpe, Jr. and Jacqueline Agnew and Karen C. Carroll and Paul J. Planet and Ronald C. Rubenstein and Allen R. Chen and Elizabeth A. Grice and Meghan F. Davis}, title = {Microbial Sharing between Pediatric Patients and Therapy Animals during Hospital Animal-Assisted Intervention Programs}, elocation-id = {2021.02.02.21250541}, year = {2021}, doi = {10.1101/2021.02.02.21250541}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Microbial sharing between humans and animals has been demonstrated in a variety of settings. However, the extent of microbial sharing that occurs within the healthcare setting during animal-assisted intervention programs, a validated and valuable part of holistic patient wellness, is unknown. Understanding microbial transmission between patients and therapy animals can provide important insights into potential health benefits for patients, in addition to addressing concerns regarding potential pathogen transmission that limits program utilization. This study evaluated the potential for microbial sharing between pediatric patients and therapy dogs, and tested whether patient-dog contact level and a dog decolonization protocol modified this sharing.Methods and Results Patients, therapy animals, and the hospital environment were sampled before and after every group therapy session and samples underwent 16S rRNA sequencing to characterize microbial communities. Both patients and animals experienced changes in the relative abundance and overall diversity of their nasal microbiome, suggesting that exchange of microorganisms had occurred. Increased contact was associated with greater sharing between patients and therapy animals, as well as between patients. A topical chlorhexidine-based dog decolonization intervention was associated with decreased microbial sharing between therapy dogs and patients, particularly from the removal of rarer microbiota from the dog, but did not significantly affect sharing between patients.Conclusion These data suggest that the therapy animal is both a potential source of and a vehicle for the transfer of microorganisms to patients but not necessarily the only source. The relative contribution of other potential sources (e.g., other patients, the hospital environment) should be further explored to determine their relative importance.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this project was supported by the Morris Animal Foundation [D15CA-802] and the National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development [5R01HD097692-02]. Funding for KRD is provided by a grant from the U.S. Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health to the Johns Hopkins Education and Research Center for Occupational Safety and Health [T42 OH0008428], and the AKC Canine Health Foundation Clinician-Scientist Fellowship [02525-E]. MFD was supported by the National Institutes of Health (K01OD019918).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was given ethical approved by the Johns Hopkins University Bloomberg School of Public Health institutional review board, and Johns Hopkins University institutional animal care and use committee, prior to data collection. All therapy dog handlers and patients{\textquoteright} parents provided written consent to participate in the study and approved having the findings published.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw sequence data and metadata can be found in NCBI Sequence Read Archive (SRA) database under BioProject PRJNA695069, BioSample SAM17600695. Unix and R code used for analysis can be found under KRD{\textquoteright}s Github repository: https://github.com/kathryndalton/AAT_pilot_analysis. https://github.com/kathryndalton/AAT_pilot_analysis}, URL = {https://www.medrxiv.org/content/early/2021/02/03/2021.02.02.21250541}, eprint = {https://www.medrxiv.org/content/early/2021/02/03/2021.02.02.21250541.full.pdf}, journal = {medRxiv} }